Works matching IS 11707690 AND DT 2025 AND VI 43 AND IP 3

Results: 8

Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukaemia: An External Assessment Group Perspective: Application of Multi-level Network Meta-Regression in the Quizartinib NICE Technology Appraisal: S. J. Nevitt et al

Published in:

PharmacoEconomics, 2025, v. 43, n. 3, p. 243, doi. 10.1007/s40273-024-01460-1

By:

Nevitt, Sarah J.;
Phillippo, David M.;
Hodgson, Robert;
Welton, Nicky J.;
Dias, Sofia

Publication type:

Article

A Multistate Model Incorporating Relative Survival Extrapolation and Mixed Time Scales for Health Technology Assessment: Multistate Model Incorporating Relative Survival Extrapolation and Mixed Time Scales for HTA: E. Y.-T. Chen et al.

Published in:

PharmacoEconomics, 2025, v. 43, n. 3, p. 297, doi. 10.1007/s40273-024-01457-w

By:

Chen, Enoch Yi-Tung;
Dickman, Paul W.;
Clements, Mark S.

Publication type:

Article

Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer: Cost-Effectiveness Analysis of Capivasertib: T. T. H Nguyen, S. Mital.

Published in:

PharmacoEconomics, 2025, v. 43, n. 3, p. 351, doi. 10.1007/s40273-024-01456-x

By:

Nguyen, Trang T. H.;
Mital, Shweta

Publication type:

Article

Economic Evaluations of Non-Pharmacological Interventions for Treating Disorders of Gut-Brain Interaction: A Scoping Review: Review of Economic Evaluations of DGBI Treatments: A. Pak et al.

Published in:

PharmacoEconomics, 2025, v. 43, n. 3, p. 249, doi. 10.1007/s40273-024-01455-y

By:

Pak, Anton;
O'Grady, Madeline;
Holtmann, Gerald;
Shah, Ayesha;
Tuffaha, Haitham

Publication type:

Article

Immediate Versus 5-Year Risk-Guided Initiation of Treatment for Primary Prevention of Cardiovascular Disease for Australians Aged 40 Years: A Health Economic Analysis: Immediate vs 5-year Risk-Guided Initiation of Treatment for Primary Prevention of CVD in Australia: J. I. Morton et al

Published in:

PharmacoEconomics, 2025, v. 43, n. 3, p. 331, doi. 10.1007/s40273-024-01454-z

By:

Morton, Jedidiah I.;
Liew, Danny;
Watts, Gerald F.;
Zoungas, Sophia;
Nicholls, Stephen J.;
Reid, Christopher M.;
Ademi, Zanfina

Publication type:

Article

Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA: Cost Effectiveness of Tremelimumab Plus Durvalumab for uHCC in the USA: X. Xiong, J. J. Guo.

Published in:

PharmacoEconomics, 2025, v. 43, n. 3, p. 271, doi. 10.1007/s40273-024-01453-0

By:

Xiong, Xiaomo;
Guo, Jeff Jianfei

Publication type:

Article

Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia: Assessing the Uncertainties in PBAC Recommendations: Q. Chen et al.

Published in:

PharmacoEconomics, 2025, v. 43, n. 3, p. 283, doi. 10.1007/s40273-024-01446-z

By:

Chen, Qunfei;
Hoyle, Martin;
Jeet, Varinder;
Gu, Yuanyuan;
Sinha, Kompal;
Parkinson, Bonny

Publication type:

Article

Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States: Public Health Impact of Introducing a Pentavalent Vaccine: H. A. Shah et al.

Published in:

PharmacoEconomics, 2025, v. 43, n. 3, p. 311, doi. 10.1007/s40273-024-01439-y

By:

Shah, Hiral Anil;
Jutlla, Ginita;
Herrera-Restrepo, Oscar;
Graham, Jonathan;
Hicks, Katherine A.;
Carrico, Justin;
Grace, Mei;
Clements, Diana E.;
Burman, Cindy;
Sohn, Woo-Yun;
Kuylen, Elise;
Begum, Shahina;
Kocaata, Zeki

Publication type:

Article